Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

PerkinElmer Pays $64 Million for China Diagnostic Company

publication date: Sep 8, 2009

PerkinElmer, Inc. completed the acquisition of SYM-BIO Lifescience, a Shanghai company that produces diagnostic instruments and their reagents. The price was $63.7 million (435 million RMB), paid in cash. The acquisition is a very good fit with PerkinElmer’s existing business. SYM-BIO Lifescience is a major supplier of diagnostics to China hospitals, with an emphasis on infectious diseases. This is complimentary to PerkinElmer’s portfolio of diagnostic devices, which specializes in prenatal and newborn screening. More details...

Stock Symbol: (NYSE: PKI)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital